Groundbreaking Results on Coronary Artery Disease Treatment
Cordis, a leader in interventional cardiovascular solutions, has unveiled the significant outcomes from the SELUTION DeNovo and SELUTION4ISR trials. These trials were presented at the prestigious Transcatheter Cardiovascular Therapeutics (TCT) 2025 event, showcasing a new era in how coronary artery disease (CAD) is approached.
SELUTION DeNovo Trial: A Milestone in Drug Eluting Balloon Technology
The SELUTION DeNovo trial marks a pivotal point in cardiovascular research, standing as the largest randomized trial focused on Drug Eluting Balloons (DEB). The trial effectively demonstrated that the SELUTION SLR™ DEB treatment strategy is non-inferior when compared to traditional Drug Eluting Stent (DES) strategies for treating de novo coronary lesions.
Key Outcomes of the Trial
Involving 3,323 patients from 62 sites globally, this trial set a record in the field of coronary DEB studies. The results revealed that SELUTION SLR™ DEB achieved target vessel failure (TVF) rates of 5.3% at 12 months, closely aligning with the DES arm at 4.4%. This compelling evidence provides robust support for considering SELUTION SLR™ DEB as a viable alternative to DES.
Expert Insights on the Findings
Professor Christian Spaulding, a co-principal investigator, emphasized the transformative nature of these findings. He noted that these results could alter the landscape of Percutaneous Coronary Intervention (PCI), allowing practitioners to minimize the reliance on stents while still ensuring effective coronary treatment options. This shift is significant for patient care, offering a safer and more effective approach with SELUTION SLR™ DEB.
SELUTION4ISR Trial: A Study on In-Stent Restenosis
The SELUTION4ISR trial also yielded promising results, focusing on patients with In-Stent Restenosis (ISR). This multicenter randomized controlled study noted that SELUTION SLR™ DEB displayed non-inferiority when compared to current ISR treatment standards. Target lesion failure (TLF) at 12-months was noted at 15.2% for SELUTION SLR™ DEB against 13.5% for standard care, showcasing the effectiveness of this treatment option.
Potential Regulatory Advancements
This positive outcome sets the stage for Cordis to pursue regulatory approval for the coronary ISR indication with the FDA. Dr. Roxana Mehran, another co-principal investigator, stated that SELUTION SLR™ DEB offers a durable solution that addresses the challenges associated with ISR without the complications that additional metal stents introduce.
Cordis' Commitment to Innovation and Patient Care
The results from both trials indicate Cordis' unwavering commitment to advancing cardiovascular treatment through innovative solutions. As a leader in the cardiac intervention arena, Cordis aims to enhance the application of drug-eluting balloons within PCI strategies.
Future Directions
With over 17,000 patients enrolled in their clinical portfolio for the SELUTION SLR™ DEB, Cordis emphasizes the importance of collaborative endeavors to push forward with meaningful innovations. The commitment to research and development will continue to evolve the treatment landscape for coronary artery disease, ultimately benefiting countless patients.
Experts Recognize Groundbreaking Contributions
Dr. Martin Leon, Chair of the Cordis Clinical Advisory Board, praised the efforts demonstrated through the SELUTION studies, citing that the findings deliver safe and effective alternatives for treating complex lesions, further enhancing patient outcomes.
About SELUTION SLR™ DEB and Cordis
SELUTION SLR™ DEB, which is commercially available in over 65 countries, is distinguished by its Sustained Limus Release (SLR) technology. This technology allows for controlled and sustained drug release for 90 days, effectively targeting the complications associated with restenosis.
Cordis has been a forerunner in cardiovascular innovation for more than six decades, introducing pioneering products that have significantly shaped the field. The organization's focus on improved clinical outcomes and customer service reflects their ongoing mission to enhance cardiovascular care for patients globally.
Frequently Asked Questions
What are the main results of the SELUTION DeNovo trial?
The SELUTION DeNovo trial showed that the SELUTION SLR™ DEB was non-inferior to drug-eluting stents in treating coronary lesions.
How many patients were involved in the SELUTION4ISR trial?
The SELUTION4ISR trial enrolled a diverse cohort of patients across multiple global sites, demonstrating crucial efficacy compared to the standard of care.
What technology does SELUTION SLR™ DEB use?
SELUTION SLR™ DEB utilizes Sustained Limus Release technology for controlled drug elution to manage restenosis effectively.
What is the potential regulatory impact of these studies?
The positive results from the trials may support Cordis in seeking FDA approval for the SELUTION SLR™ DEB's application in ISR treatment.
How has Cordis contributed to cardiovascular treatment advancements?
Cordis has consistently driven innovation in cardiovascular technology, reshaping how coronary artery disease is treated over the last 60 years.
